These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Dougherty JA; Guirguis E; Thornby KA Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083 [TBL] [Abstract][Full Text] [Related]
8. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. Dihoum A; Rena G; Pearson ER; Lang CC; Mordi IR Expert Opin Investig Drugs; 2023 Apr; 32(4):291-299. PubMed ID: 36972373 [TBL] [Abstract][Full Text] [Related]
9. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388 [TBL] [Abstract][Full Text] [Related]
10. Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. Janjusevic M; Fluca AL; Gagno G; Pierri A; Padoan L; Sorrentino A; Beltrami AP; Sinagra G; Aleksova A Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216451 [TBL] [Abstract][Full Text] [Related]
11. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028 [TBL] [Abstract][Full Text] [Related]
12. Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs. Goodarzi G; Tehrani SS; Fana SE; Moradi-Sardareh H; Panahi G; Maniati M; Meshkani R Metab Brain Dis; 2023 Aug; 38(6):1769-1800. PubMed ID: 37335453 [TBL] [Abstract][Full Text] [Related]
13. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?]. García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Scheen AJ Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
16. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease. Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822 [TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402 [TBL] [Abstract][Full Text] [Related]
18. How to fight obesity with antidiabetic drugs: targeting gut or kidney? Baretić M; Troskot R Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984 [TBL] [Abstract][Full Text] [Related]
19. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280 [TBL] [Abstract][Full Text] [Related]
20. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Rahelić D; Javor E; Lucijanić T; Skelin M Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]